维多珠单抗暴露水平与溃疡性结肠炎临床结局:确定剂量优化的潜力
该研究基于GEMINI 1试验和先前群体药代动力学研究数据,采用倾向评分匹配分析,在校正年龄、体重、抗肿瘤坏死因子α治疗史、血清白蛋白和粪便钙卫蛋白后,探讨维多珠单抗暴露与溃疡性结肠炎临床缓解的关系,并提出第6、14周及稳态的潜在目标浓度分别为37.1、18.4和12.7 µg/mL。
要点
- 第6周维多珠单抗浓度与第14周和第52周临床缓解持续相关。
- 提出的潜在目标浓度为第6周37.1 µg/mL、第14周18.4 µg/mL、稳态12.7 µg/mL。
- 这些目标浓度仅供进一步研究,原文未据此给出剂量调整推荐。
核心结论
- 在校正潜在混杂因素后,第6周维多珠单抗浓度与短长期临床缓解相关,提出的诱导和维持目标浓度有待进一步研究。
研究设计与样本
- 基于GEMINI 1试验和一项早期大型群体药代动力学研究数据,采用倾向评分匹配病例匹配分析,以维多珠单抗清除率或浓度为临床缓解和应答的预测因素,校正年龄、体重、抗肿瘤坏死因子α治疗史、血清白蛋白和粪便钙卫蛋白浓度;评估第2、4、6周早期浓度与第14、52周临床缓解的关联。
- 第6周有药代动力学数据的患者共693例。
主要发现
- 第6周、第14周和稳态的潜在目标维多珠单抗浓度分别为37.1、18.4和12.7 µg/mL。
- 第6周被确定为维多珠单抗浓度与第14周和第52周临床缓解持续相关的最早时间点。
关键数值与推荐
- 潜在目标浓度:第6周37.1 µg/mL,第14周18.4 µg/mL,稳态12.7 µg/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prospectively designed studies assessing the exposure-response profile of vedolizumab are lacking. Observational exposure-response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly those that may affect vedolizumab clearance. AIMS: To (a) investigate the vedolizumab exposure-response relationship after adjusting for potential confounding variables; (b) propose potential target serum vedolizumab concentrations for future study; (c) ascertain whether early vedolizumab serum concentrations were associated with short- and long-term clinical outcomes in adults with ulcerative colitis in GEMINI 1. METHODS: Propensity-score-based case-matching analysis was performed using data from GEMINI 1 and an earlier large population pharmacokinetic study, with vedolizumab clearance or concentration as predictors of clinical remission and response, adjusted for age, weight, anti-tumour necrosis factor alpha therapy history, serum albumin and faecal calprotectin concentrations. Potential vedolizumab concentration targets at weeks 6, 14 and steady state were proposed. Association between early vedolizumab concentrations at weeks 2, 4 and 6 and clinical remission at weeks 14 and 52 was evaluated. RESULTS: Among 693 patients with pharmacokinetic data at week 6, potential target vedolizumab concentrations at weeks 6, 14 and steady state were 37.1, 18.4 and 12.7 µg/mL respectively. Week 6 was identified as the earliest time at which vedolizumab concentrations were consistently associated with clinical remission at weeks 14 and 52. CONCLUSIONS: In this comprehensively adjusted analysis, vedolizumab concentrations at week 6 were associated with short- and long-term remission. Potential induction and maintenance target concentrations were proposed for further study.
引用
- Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther. 2019. PMID: 30663076. doi:10.1111/apt.15113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。